{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:38:59Z","timestamp":1786984739347,"version":"build-2736575974"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100010067","name":"Gobierno de Arag\u00f3n","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010067","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cl\u00ednica e Investigaci\u00f3n en Arteriosclerosis"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.arteri.2021.01.002","type":"journal-article","created":{"date-parts":[[2021,5,15]],"date-time":"2021-05-15T08:40:19Z","timestamp":1621068019000},"page":"50-55","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"S2","title":["Disbetalipoproteinemia y otras alteraciones relacionadas con la apolipoprote\u00edna E"],"prefix":"10.1016","volume":"33","author":[{"given":"Ana","family":"Cenarro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana M.","family":"Bea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Gracia-Rubio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Civeira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.arteri.2021.01.002_bib0145","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/jid.1952.66","article-title":"Lipoproteins and xanthomatous diseases","volume":"19","author":"McGinley","year":"1952","journal-title":"J Invest Dermatol."},{"key":"10.1016\/j.arteri.2021.01.002_bib0150","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJM196701052760107","article-title":"Fat transport in lipoproteins--an integrated approach to mechanisms and disorders","volume":"276","author":"Fredrickson","year":"1967","journal-title":"N Engl J Med."},{"key":"10.1016\/j.arteri.2021.01.002_bib0155","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1080\/10408363.2020.1745142","article-title":"The clinical and laboratory investigation of dysbetalipoproteinemia","volume":"57","author":"Boot","year":"2020","journal-title":"Crit Rev Clin Lab Sci."},{"key":"10.1016\/j.arteri.2021.01.002_bib0160","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.5114\/aoms.2019.86964","article-title":"Modern prevalence of the Fredrickson-Levy-Lees dyslipidemias: findings from the Very Large Database of Lipids and National Health and Nutrition Examination Survey","volume":"16","author":"Sathiyakumar","year":"2019","journal-title":"Arch Med Sci."},{"key":"10.1016\/j.arteri.2021.01.002_bib0165","first-page":"248","article-title":"National Dyslipidemia Registry of the Spanish Arteriosclerosis Society: Current status","volume":"29","author":"P\u00e9rez-Calahorra","year":"2017","journal-title":"Clin Investig Arterioscler."},{"key":"10.1016\/j.arteri.2021.01.002_bib0170","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/j.jacl.2018.09.006","article-title":"The spectrum of type III hyperlipoproteinemia","volume":"12","author":"Sniderman","year":"2018","journal-title":"J Clin Lipidol."},{"key":"10.1016\/j.arteri.2021.01.002_bib0175","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1373\/clinchem.2018.292425","article-title":"Evaluation of the Non-HDL Cholesterol to Apolipoprotein B Ratio as a Screening Test for Dysbetalipoproteinemia","volume":"65","author":"Boot","year":"2019","journal-title":"Clin Chem."},{"key":"10.1016\/j.arteri.2021.01.002_bib0180","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.jacl.2020.06.004","article-title":"A simplified diagnosis algorithm for dysbetalipoproteinemia","volume":"14","author":"Paquette","year":"2020","journal-title":"J Clin Lipidol."},{"key":"10.1016\/j.arteri.2021.01.002_bib0185","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1097\/00041433-199906000-00003","article-title":"Apolipoprotein E: from atherosclerosis to Alzheimer's disease and beyond","volume":"10","author":"Mahley","year":"1999","journal-title":"Curr Opin Lipidol."},{"key":"10.1016\/j.arteri.2021.01.002_bib0190","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.pathol.2018.11.002","article-title":"in lipoprotein metabolism, health and cardiovascular disease","volume":"51","author":"Marais","year":"2019","journal-title":"Pathology."},{"key":"10.1016\/j.arteri.2021.01.002_bib0195","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1055\/s-2004-861492","article-title":"Apolipoprotein E and familial dysbetalipoproteinemia: clinical, biochemical, and genetic aspects","volume":"4","author":"Smelt","year":"2004","journal-title":"Semin Vasc Med."},{"key":"10.1016\/j.arteri.2021.01.002_bib0200","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/S0022-2275(20)38060-3","article-title":"Studies of familial type III hyperlipoproteinemia using as a genetic marker the apoE phenotype E2\/2","volume":"23","author":"Breslow","year":"1982","journal-title":"J Lipid Res."},{"key":"10.1016\/j.arteri.2021.01.002_bib0205","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1172\/JCI110330","article-title":"Familial dysbetalipoproteinemia, Abnormal binding of mutant apoprotein E to low density lipoprotein receptors of human fibroblasts and membranes from liver and adrenal of rats, rabbits, and cows","volume":"68","author":"Schneider","year":"1981","journal-title":"J Clin Invest."},{"key":"10.1016\/j.arteri.2021.01.002_bib0210","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1146\/annurev.genom.1.1.507","article-title":"Apolipoprotein E: far more than a lipid transport protein","volume":"1","author":"Mahley","year":"2000","journal-title":"Annu Rev Genomics Hum Genet."},{"key":"10.1016\/j.arteri.2021.01.002_bib0215","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S0021-9150(96)05969-2","article-title":"Apo E variants in patients with type III hyperlipoproteinemia","volume":"127","author":"Civeira","year":"1996","journal-title":"Atherosclerosis."},{"key":"10.1016\/j.arteri.2021.01.002_bib0220","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0021-9150(95)06745-0","article-title":"Incomplete dominance of type III hyperlipoproteinemia is associated with the rare apolipoprotein E2 (Arg136-->Ser) variant in multigenerational pedigree studies","volume":"122","author":"Pocovi","year":"1996","journal-title":"Atherosclerosis."},{"key":"10.1016\/j.arteri.2021.01.002_bib0225","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.atherosclerosis.2012.03.011","article-title":"Apolipoprotein E gene mutations in subjects with mixed hyperlipidemia and a clinical diagnosis of familial combined hyperlipidemia","volume":"222","author":"Solanas-Barca","year":"2012","journal-title":"Atherosclerosis."},{"key":"10.1016\/j.arteri.2021.01.002_bib0230","doi-asserted-by":"crossref","first-page":"14813","DOI":"10.1073\/pnas.1106420108","article-title":"Topology of human apolipoprotein E3 uniquely regulates its diverse biological functions","volume":"108","author":"Chen","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.arteri.2021.01.002_bib0235","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1021\/bi9017208","article-title":"Decoding of lipoprotein\u2013 receptor interactions; Properties of ligand binding modules governing interactions with ApoE","volume":"49","author":"Guttman","year":"2010","journal-title":"Biochemistry"},{"key":"10.1016\/j.arteri.2021.01.002_bib0240","series-title":"The Metabolic and Molecular Bases of Inherited Disease","first-page":"1953","article-title":"Type III hyperlipoproteinemia (dysbetalipoproteinemia): the role of apolipoprotein E in normal and abnormal lipoprotein metabolism","author":"Mahley","year":"1995"},{"key":"10.1016\/j.arteri.2021.01.002_bib0245","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.jacl.2014.05.004","article-title":"Severe hypercholesterolemia and phytosterolemia with extensive xanthomas in primary biliary cirrhosis: role of biliary excretion on sterol homeostasis","volume":"8","author":"Baila-Rueda","year":"2014","journal-title":"J Clin Lipidol."},{"key":"10.1016\/j.arteri.2021.01.002_bib0250","series-title":"Hiperlipemias. Cl\u00ednica y tratamiento","first-page":"117","article-title":"Hiperlipoproteinemia tipo III (disbetalipoproteinemia)","author":"Carmena","year":"1999"},{"key":"10.1016\/j.arteri.2021.01.002_bib0255","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.jacc.2004.11.062","article-title":"Plasma triglycerides and type III hyperlipidemia are independently associated with premature familial coronary artery disease","volume":"45","author":"Hopkins","year":"2005","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.arteri.2021.01.002_bib0260","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.atherosclerosis.2015.02.046","article-title":"Vascular risk factors, vascular disease, lipids and lipid targets in patients with familial dysbetalipoproteinemia: a European cross-sectional study","volume":"240","author":"Koopal","year":"2015","journal-title":"Atherosclerosis."},{"key":"10.1016\/j.arteri.2021.01.002_bib0265","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacl.2020.05.027","article-title":"Importance of the triglyceride level in identifying patients with a Type III Hyperlipoproteinemia phenotype using the ApoB algorithm","author":"Varghese","year":"2020","journal-title":"J Clin Lipidol."},{"issue":"1 Pt 1","key":"10.1016\/j.arteri.2021.01.002_bib0270","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/S0002-8703(99)70262-0","article-title":"Comparison of the hypolipidemic effect of gemfibrozil versus simvastatin in patients with type III hyperlipoproteinemia","volume":"138","author":"Civeira","year":"1999","journal-title":"Am Heart J."},{"key":"10.1016\/j.arteri.2021.01.002_bib0275","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1373\/clinchem.2018.298026","article-title":"Type III Hyperlipoproteinemia: The Forgotten, Disregarded, Neglected, Overlooked, Ignored but Highly Atherogenic, and Highly Treatable Dyslipoproteinemia","volume":"65","author":"Sniderman","year":"2019","journal-title":"Clin Chem."},{"key":"10.1016\/j.arteri.2021.01.002_bib0280","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1136\/heart.88.3.234","article-title":"Long term efficacy and safety of atorvastatin in the treatment of severe type III and combined dyslipidaemia","volume":"88","author":"Van Dam","year":"2002","journal-title":"Heart."}],"container-title":["Cl\u00ednica e Investigaci\u00f3n en Arteriosclerosis"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0214916821000139?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0214916821000139?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T13:33:28Z","timestamp":1759325608000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0214916821000139"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":28,"alternative-id":["S0214916821000139"],"URL":"https:\/\/doi.org\/10.1016\/j.arteri.2021.01.002","relation":{},"ISSN":["0214-9168"],"issn-type":[{"value":"0214-9168","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Disbetalipoproteinemia y otras alteraciones relacionadas con la apolipoprote\u00edna E","name":"articletitle","label":"Article Title"},{"value":"Cl\u00ednica e Investigaci\u00f3n en Arteriosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.arteri.2021.01.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Sociedad Espa\u00f1ola de Arteriosclerosis. Published by Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}